EYEN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 20:26):

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology...

Stats
Dagens volum	2.14M
Gjennomsnittsvolum	1.33M
Markedsverdi	53.25M
EPS	$0 ( 2024-03-18 )
Neste inntjeningsdato	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.580
ATR14	$0.00500 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Grant Stuart M.	Buy	100 000	Common stock, par value $0.0001
2024-03-19	Grant Stuart M.	Buy	50 000	Common stock, par value $0.0001
2024-03-08	Grant Stuart M.	Buy	10 717	Common stock, par value $0.0001
2024-02-12	Gandolfo John P	Buy	60 000	Stock Option (right to buy)
2024-02-12	Rowe Michael M	Buy	75 000	Stock Option (right to buy)

INSIDER POWER
68.95
Last 95 transactions
Buy: 2 919 948 \| Sell: 334 000

Volum Korrelasjon

Lang: -0.35 (neutral)

Kort: 0.55 (weak)

Signal:(50.336) Neutral

Eyenovia Inc Korrelasjon

10 Mest positive korrelasjoner
WINA	0.968
INZY	0.966
CSPI	0.955
AZ	0.948
HROW	0.946
ESCA	0.944
VMD	0.944
HSKA	0.944
BRLI	0.944
THAC	0.942

10 Mest negative korrelasjoner
CYRN	-0.957
TLGT	-0.936
GNTY	-0.935
FVCB	-0.934
CDXC	-0.933
ONEM	-0.933
PEAR	-0.93
RPRX	-0.93
BWB	-0.929
AROW	-0.927

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Eyenovia Inc Korrelasjon - Valuta/Råvare

-0.25
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.38
( neutral )

Eyenovia Inc Økonomi

Annual	2023
Omsetning:	$3 787.00
Bruttogevinst:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

FY	2023
Omsetning:	$3 787.00
Bruttogevinst:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

FY	2022
Omsetning:	$0
Bruttogevinst:	$-307 430 (0.00 %)
EPS:	$-0.820

FY	2021
Omsetning:	$14.00M
Bruttogevinst:	$12.40M (88.57 %)
EPS:	$-0.607

Financial Reports:

No articles found.

Eyenovia Inc

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.